

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on January 18, 2007.

PATENT
Attorney Docket No.: 082368-003300US
Client Reference No.: E1-A0306Y1P-US

TOWNSEND and TOWNSEND and CREW LLP

By: /Brien M. Bergner/
Brien M. Bergner

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

YASUDA , Nobuyuki and Kazuto
Yamazaki

Application No.: 10/528,353

Filed: January 3, 2006

For: COMBINATION DRUG

Confirmation No.: 5028

Examiner: RAE, Charlesworth E.

Art Unit: 1615

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In compliance with the requirements of 37 CFR §1.98(a)(2), copies of U.S. references AO-AT are not enclosed; copies of references AU-BB are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Reference AU was cited in an Office Action issued in the corresponding Singapore application. This reference is not in English, and a concise explanation of relevance is not provided since reference AQ is an application from the same family.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

/Kevin Bastian/

Kevin Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KLB:bmb
60955590 v1

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/528,353
				Filing Date	January 3, 2006
				First Named Inventor	Yasuda, Nobuyuki
				Art Unit	1615
				Examiner Name	RAE, Charlesworth E.
Sheet	1	of	2	Attorney Docket Number	082368-003300US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	AO	US-6,011,155 A	01-04-2000	VILLHAUER, Edwin B.	
	AP	US-6,166,063 A	12-26-2000	VILLHAUER, Edwin B.	
	AQ	US-6,548,481 B1	04-15-2003	DEMUTH, Hans-Ulrich, <i>et al.</i>	
	AR	US-2002-0161001 A1	10-31-2002	KANSTRUP, Anders B., <i>et al.</i>	
	AS	US-2002-0198205 A1	12-26-2002	HIMMELSBACH, Frank, <i>et al.</i>	
	AT	US-2003-0105077 A1	06-05-2003	KANSTRUP, Anders B., <i>et al.</i>	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AU	WO	99/61431	A1	12-02-1999	Pro-Biodrug Gesellschaft Für Arzneimittelforschung mbH		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AV	BOUSHEY, Robin P., <i>et al.</i> ; "Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis;" <u>American Journal of Physiology</u> ; 1999; pp. E937-47; 277: (5 Pt. 1).	<input type="checkbox"/>	
	AW	BOUSHEY, Robin P., <i>et al.</i> ; "Glucagon-like Peptide (GLP)-2 Reduces Chemotherapy-associated Mortality and Enhances Cell Survival in Cells Expressing a Transfected GLP-2 Receptor;" <u>Cancer Research</u> ; January 15, 2001; pp. 687-693; 61:2.	<input type="checkbox"/>	
	AX	DRUCKER, Daniel J.; "Biological Actions and Therapeutic Potential of the Glucagon-like Peptides;" <u>Gastroenterology</u> ; 2002; pp. 531-544; 122:2.	<input type="checkbox"/>	
	AY	DRUCKER, Daniel J.; "Get adaptation and the glucagon-like peptides;" <u>Gut</u> ; July 14, 2005; pp. 428-435; 50:3.	<input type="checkbox"/>	
	AZ	MANNUCCI, Edoardo, <i>et al.</i> ; "Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects;" <u>Diabetes Care</u> ; March 2001; pp. 489-494; 24:3.	<input type="checkbox"/>	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/528,353
				Filing Date	January 3, 2006
				First Named Inventor	Yasuda, Nobuyuki
				Art Unit	1615
				Examiner Name	RAE, Charlesworth E.
Sheet	2	of	2	Attorney Docket Number	082368-003300US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	BA	SIGALET, David L.; "ALX-0600 NPS Allelix Corp;" <u>Current Opinion in Investigational Drugs</u> ; 2001; pp. 505-509; 2:4.	<input type="checkbox"/>	
	BB	ZANDER, Mette, <i>et al.</i> ; "Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes;" <u>Diabetes Care</u> ; April 2001; pp. 720-725; 24:4.	<input type="checkbox"/>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.